Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab

Monoclonal antibody (mAb) drugs have been widely used for treating tumor necrosis factor α (TNFα)-related diseases for over 10 years. Although their action has been hypothesized to depend in part on their ability to bind precursor cell surface TNFα, the precise mechanism and the epitope bound on TNF...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Liang, Shuaiyi, Dai, Jianxin, Hou, Sheng, Su, Lishu, Zhang, Dapeng, Guo, Huaizu, Hu, Shi, Wang, Hao, Rao, Zihe, Guo, Yajun, Lou, Zhiyong
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society for Biochemistry and Molecular Biology 2013
الموضوعات:
Immunology
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3650416/
https://ncbi.nlm.nih.gov/pubmed/23504311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M112.433961
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة